Alimera Sciences, Inc.

NasdaqGM:ALIM Stock Report

Market Cap: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences Future Growth

Future criteria checks 4/6

Alimera Sciences is forecast to grow earnings and revenue by 62.7% and 16.3% per annum respectively while EPS is expected to grow by 63.1% per annum.

Key information

62.7%

Earnings growth rate

63.14%

EPS growth rate

Pharmaceuticals earnings growth14.8%
Revenue growth rate16.3%
Future return on equityn/a
Analyst coverage

Low

Last updated25 Jun 2024

Recent future growth updates

Recent updates

Seeking Alpha • Sep 11

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Summary Alimera Sciences, Inc. is being acquired by ANI Pharmaceuticals for $5.50 per share, with a contingent value right, or CVR, potentially adding up to $0.50 per share. Despite initial delays and Alimera suing ANI to close the deal, ANI remains committed, expecting to resolve closing conditions promptly. The deal is highly synergistic, adding durable assets to ANI's portfolio, with significant revenue growth and accretion expected by 2025. At $5.54 per share, Alimera Sciences stock is attractive, offering potential CVR payouts based on achievable sales targets, making it a compelling investment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Alimera Sciences: Cheap CVR Optionality

Summary Alimera Sciences is being acquired by a larger peer at $5.5/share + CVR of up to 50 cents. In this article, I will focus on a CVR play with only a 10-cent outlay and a potential payout of up to 50 cents. The merger-related risks are minimal, and there are arguments that suggest the CVR milestones could be met. Read the full article on Seeking Alpha
Analysis Article • Jun 18

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

You may think that with a price-to-sales (or "P/S") ratio of 1.9x Alimera Sciences, Inc. ( NASDAQ:ALIM ) is a stock...
Analysis Article • Feb 15

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right...
Analysis Article • Dec 30

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Oct 13

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

There wouldn't be many who think Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.5x is...
Analysis Article • Sep 13

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Oct 06

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera Sciences (NASDAQ:ALIM) said on Thursday a post-hoc analyses from a Phase 4 study showed that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Iluvien provides diabetic macular edema patients with continuous therapy for up to 36 months. The treatment significantly reduced the number of eyes requiring anti-VEGF, corticosteroid, and laser therapy and reduced the total number of therapies administered by 46%. Iluvien is a intravitreal implant in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Seeking Alpha • Sep 20

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Ireland. ALIM said the reimbursement was granted to the its Ireland-based European unit by the Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland. The reimbursement decision by Ireland adds to a string of such grants earlier this year by Portugal, France and Italy. "We continue to expand the availability of our non-infectious uveitis indication in our International Segment with it now accessible to patients in all of our direct markets in addition to our key distributor markets," ALIM CEO Rick Eiswirth said in a statement. ALIM stock closed -3.6% at $5.38 on Monday.
Seeking Alpha • Aug 09

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal. ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and Health Products with no change to the current label. The reimbursement decision by Portugal follows similar approvals for Iluvien in France and Italy in July. “This summer has been a productive one for expanding availability of our non-infectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets,” ALIM CEO Rick Eiswirth said in a statement. ALIM said it is planning to launch Iluvien in Portugal and France in Q3. Alimera (ALIM) stock closed +2.6% at $7.18 on Monday.
Seeking Alpha • Jul 22

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval for Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products. Alimera (ALIM) did not disclose the pricing determination for Iluvien. Earlier in July, ALIM got Italian regulatory approval and was granted pricing and reimbursement for Iluvien for the same indication. ALIM stock closed +0.8% at $5.33 on Thursday.
Seeking Alpha • Jul 08

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences (NASDAQ:ALIM) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation. ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement for Iluvien by the Italian Medicines Agency (AIFA), Alimera said in a statement on Friday. The indication was for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. ALIM said it would launch Iluvien through its Italian distribution partner, ophthalmic company SIFI. It did not disclose the pricing determination for Iluvien. ALIM stock closed marginally higher at $5.32 on Thursday.
Analysis Article • Mar 24

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Nov 06

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alimera Sciences, Inc...
Analysis Article • Aug 24

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Even though Alimera Sciences, Inc. ( NASDAQ:ALIM ) posted strong earnings recently, the stock hasn't reacted in a large...
Analysis Article • Feb 11

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences, Inc. ( NASDAQ:ALIM ) shareholders will doubtless be very grateful to see the share price up 97% in...

Earnings and Revenue Growth Forecasts

NasdaqGM:ALIM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261362452N/A3
12/31/20251211037N/A4
12/31/2024106-732N/A4
6/30/2024100-15-6-6N/A
3/31/202490-23-88-13N/A
12/31/202381-21-90-14N/A
9/30/202368-21-94-18N/A
6/30/202359-25-86-10N/A
3/31/202356-17-6-6N/A
12/31/202254-18-10-10N/A
9/30/202254-18-15-14N/A
6/30/202253-17-16-15N/A
3/31/202260-7-8-7N/A
12/31/202159-4-4-3N/A
9/30/202159-111N/A
6/30/202159212N/A
3/31/202147-8-6-5N/A
12/31/202051-5-3-2N/A
9/30/202054-4-2-2N/A
6/30/202055-6-4-3N/A
3/31/202056-9-4-4N/A
12/31/201954-10-4-4N/A
9/30/201952-12-4-4N/A
6/30/20195019-4-4N/A
3/31/20195022-6-6N/A
12/31/20184717-12-12N/A
9/30/20184111-14-14N/A
6/30/201839-22-14-14N/A
3/31/201839-23N/A-14N/A
12/31/201736-22N/A-13N/A
9/30/201737-21N/A-14N/A
6/30/201736-25N/A-18N/A
3/31/201735-29N/A-23N/A
12/31/201634-33N/A-25N/A
9/30/201629-38N/A-32N/A
6/30/201628-30N/A-32N/A
3/31/201624-32N/A-37N/A
12/31/201522-31N/A-45N/A
9/30/201518-30N/A-46N/A
6/30/201514-35N/A-42N/A
3/31/201510-26N/A-33N/A
12/31/20148-37N/A-24N/A
9/30/20148-41N/A-25N/A
6/30/20146-36N/A-29N/A
3/31/20144-58N/A-34N/A
12/31/20132-51N/A-38N/A
9/30/20131-42N/A-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALIM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: ALIM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALIM is expected to become profitable in the next 3 years.

Revenue vs Market: ALIM's revenue (16.3% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: ALIM's revenue (16.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALIM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/18 13:44
End of Day Share Price 2024/09/13 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alimera Sciences, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Caroline CornerCantor Fitzgerald & Co.